UNSPSC 51294523: Paroxetine mesilate or mesylate

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C19H20FNO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M711N184JE, chemically known as piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3s,4r)-, methanesulfonate (1:1), but more generally known as paroxetine mesylate, which bears US NIH Compound Identifier 206527.

UNSPSC 51294523 Paroxetine mesilate or mesylate is a Commodity code representing pharmaceutical products, yet the recent state and local procurement activity tagged to it shows a substantial mismatch with this nominal scope. The single recent opportunity on record — Seminole County, Florida's IFB60459723LAS — solicits naloxone and drug deactivation systems, not paroxetine or psychiatric medications. State and local governments buying under this code appear to do so inconsistently or infrequently; the taxonomy assignment does not reflect the actual goods being procured in the visible opportunity set.

Seminole County issued the naloxone and drug deactivation systems IFB on June 30, 2026, with a response deadline of July 26, 2023 (note: the deadline predates the posting date by nearly three years in the source data, suggesting a data integrity issue). The procurement seeks 1,900 units of naloxone and 800 drug deactivation systems annually for delivery to the Seminole County Community Health Building in Sanford, Florida, with quarterly deliveries and fixed-fee pricing. The contract runs two years with an optional one-year renewal; vendors must meet E-Verify compliance, drug-free workplace certification, and insurance requirements including workers' compensation and commercial general liability. The opportunity may be FEMA-funded and includes a three-month probationary termination clause. No explicit set-aside designations are noted. Beyond Seminole County, no other state or local issuing bodies appear in the recent record for this code, and no geographic concentration can be established from a single opportunity. The mismatch between the pharmaceutical code descriptor and the naloxone procurement signals either a tagging error or dormant activity under the paroxetine code itself among state and local buyers.